Roche (JOBS), Biogen Idec, Inc. (Massachusetts)'s (JOBS) Rituxan Stops Lymphoma from Worsening in Study
Reuters -- Follicular lymphoma patients receiving Roche (ROG.VX) and Biogen Idec's (BIIB.O) cancer drug Rituxan lived longer without their disease getting worse in a late stage study, the companies said.